Efficiency of Non-Invasive Prenatal Testing in Detecting Fetal Copy Number Variation: A Retrospective Cohort Study
Li Yang,Jing Yang,Guosen Bu,Rui Han,Jiamila Rezhake,Xiaolin La
DOI: https://doi.org/10.2147/ijwh.s479747
2024-10-04
International Journal of Women s Health
Abstract:Li Yang, 1 Jing Yang, 2 Guosen Bu, 3 Rui Han, 1 Jiamila Rezhake, 1 Xiaolin La 1 1 Center of Reproductive Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China; 2 Department of Gynaecology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, People's Republic of China; 3 Department of Neurology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China Correspondence: Xiaolin La, Center of Reproductive Medicine, The First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushannan Road, Urumqi, 830054, People's Republic of China, Tel +86-991-4362889, Email Purpose: Screening of pathological copy number variations (CNVs) is important for early-diagnosis of hereditary disease. This study was designed to investigate the efficiency of non-invasive prenatal testing (NIPT) in detecting fetal CNVs. Methods: This retrospective analysis included fetuses with CNVs between January 2018 and December 2020. Karyotype analysis and CNV sequencing (CNV-seq) were performed. We then analyzed the positive predictive values of the subchromosomal microdeletions and microduplications. Results: Fifty-eight subjects with aberrant CNVs were screened after NIPT, among which 44 finally underwent amniocentesis. CNV-seq confirmed the presence of CNVs in 24 cases. This indicated that false positivity rate of NIPT was 45.5%. Among 24 cases with CNVs after CNV-seq, only 4 showed consistent findings with karyotype analysis, which showed that karyotyping analysis yielded a missed diagnosis rate of 83.3% for the genome CNV. Positive predictive value (PPV) was 50.0% for CNVs with a length of < 5 Mb after NIPT screening. PPV for CNVs with a length of 5 Mb-10 Mb was 33.3%, while that for CNVs with a length of ≥ 10Mb was 60%. For CNVs duplication after NIPT, the PPV was 65.2%, while that for deletion was 36.4%. Conclusion: For CNVs detected after NIPT, it should be combined with ultrasonographic findings, karyotype analysis, CNV-seq or CMA to determine the pregnancy outcome. Expanding NIPT may increase the risk of unnecessary invasive surgery and unintended selective termination of pregnancy. Keywords: non-invasive prenatal screening, genome copy number variation, next-generation sequencing, prenatal diagnosis Chromosomal abnormalities are gradually becoming the key cause for mortality and morbidity among fetuses, 1,2 including chromosome numerical abnormality, deletion or duplication, as well as pathogenic copy number variants (pCNVs). To date, prenatal screening, preimplantation genetic testing and prenatal diagnosis are effective for prevention of these conditions among fetuses. 3,4 Noninvasive prenatal testing (NIPT) is based on the analysis of fetal cell-free DNA (cfDNA) in maternal blood for the detection of fetal chromosome abnormalities in high-risk pregnancies. NIPT for Trisomies 21, 18, and 13 has been common in clinical practice with a sensitivity of over 99% worldwide. 5 Since 2015, NIPT has been recommended as the first-line method for prenatal screening by the International Society for Prenatal Diagnosis (ISPD). 6 Nowadays, it has been utilized in the prenatal diagnosis of the aneuploidy of the whole chromosome. 7 Theoretically, NIPT could also detect the chromosomal microdeletions, microduplications, or CNVs. 8 Unlike common trisomies, the incidence of CNVs is independent of maternal age. 9 Due to a lack of effective screening methods for fetal chromosome CNVs, pregnant women may benefit from prenatal NIPT testing by providing reference for subsequent invasive prenatal diagnosis. This is beneficial for early clinical diagnosis and intervention, and more efficient prevention of birth defects. However, the widespread implementation of CNV detection in standard prenatal screening is limited, as the sensitivity in reflecting the genome anomaly is still under investigation. In addition, there is still a lack of studies with large sample sizes focusing on the clinical utility of NIPT in CNVs screening. Next-generation sequencing (NGS)-based CNV-sequencing (CNV-seq) contributes to the screening of CNVs in the human genome, which is featured by high throughput, high resolution and no need for cell culture. 10,11 Therefore, it has been commonly utilized in the prenatal diagnosis. CNV-seq could precisely localize the fracture site for the micro-structural aberration and confirm the size of the chromosomal aberration. 12 In addition, it could precisely analyze the effects of chromosomal structural aberration on the clinical phenotype -Abstract Truncated-
obstetrics & gynecology